Data from EMA (European Medicines Agency) - Curated by EPG Health - Last updated 13 June 2018

Indication(s)

Zerbaxa is indicated for the treatment of the following infections in adults:
- Complicated intra-abdominal infections;
- Acute pyelonephritis;
- Complicated urinary tract infections.

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

Full Prescribing information

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Fluid Management

Fluid Management

Are you up-to-date with the latest evidence of effective procedures for fluid management?

+ 2 more

Inflammatory bowel disease assessment tools

Inflammatory bowel disease assessment tools

'New IBD assessment tools at a glance' - an educational symposium sponsored by Sandoz.

Fibrinogen Deficiency in Bleeding

Fibrinogen Deficiency in Bleeding

Fibrinogen is important for blood clot formation and breakdown. It is the first coagulant factor to be reduced to critical levels during massive trauma, cardiac surgery and postpartum haemorrhage that involve excessive bleeding. Persistent fibrinogen deficiency can lead to bleeding complications and an increased risk in mortality. This learning zone looks at both congenital and acquired fibrinogen deficiencies including indications and techniques for diagnosis, trigger level for treatment and treatment options.

Load more

Related Content

More information

Category Value
Agency product number EMEA/H/C/003772
Orphan designation No
Date First Approved 18-09-2015
Type Medicinal product subject to medical prescription
Marketing authorisation holder Merck Sharp & Dohme Limited
Warnings This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions